Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2) - Wikidata - wikimedia - TriplyDB

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

http://www.wikidata.org/entity/Q37631758

about

Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization Hepatitis C treatment: where are we now?Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.Retrospective analysis of hepatitis C infected patients treated through an integrated care model.Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.Hepatitis C virus resistance to the new direct-acting antivirals.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues.Management of direct antiviral agent failures.Treatment Options in Hepatitis C.Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Real-world challenges for hepatitis C virus medications: a critical overview.Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients.Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.

P2860

Q26746563-9A51E826-899E-4458-8282-A22D3A98B5E7 Q28075544-6BCDC3E3-EBCC-4A57-A946-1325E67D71EF Q28079102-E6EB58B7-D72E-45E3-816C-3FF4D8B4CE94 Q30378509-AD539198-F92C-49CB-A61B-13862E449DB1 Q31160142-9B654CD1-F736-430E-B815-2EB0A8569304 Q33560181-C89C50C6-012C-4620-B5B5-68EE2705FEF4 Q33585021-1AD0D607-4CC5-4029-86A1-25528D69BC39 Q33629092-8E49BCCF-E16B-47C2-9E52-053F1DA56463 Q36077546-FC5DADD7-19AB-4A86-B7D3-DDB86566BCE4 Q36145716-B9867C17-E91A-4270-8AF6-4051D0C30169 Q36261373-4667E659-071C-4254-BA23-3A8E740B1BB2 Q36299928-8826B5EE-476F-42C0-A83E-393C5A14ACB4 Q37338952-7C08D354-52A5-45B4-8F0B-6C8349C35183 Q37682673-4FBDB088-E180-4288-BFEC-4F00DC276F7B Q38618427-3299F38A-F4C3-44CD-A877-855D83B8B19D Q38751552-30287B89-A312-4509-92F7-98C412DAF720 Q38798462-8166972D-56FC-41A0-BC20-CB1256683211 Q38887954-B3C1EECC-22C7-4A6B-ACF6-63BB83F73AA6 Q38893244-B43D1ABB-4E8D-4CFB-88BE-64D520A82169 Q38927205-D8D9CD44-BFB6-476B-92E4-5C2119090E71 Q38933599-B1622B2A-8690-4F53-A806-DC11E492D49E Q38954096-E69AC49B-AB71-4B30-8652-73D6666CB479 Q38972180-B3285E62-815B-4F05-836F-4A11D85AF498 Q38978908-1D210A07-F761-4859-9BE1-984DA9ED13DF Q39002714-7C1FCED1-CBC5-4297-B91B-52446DC7D46D Q39024201-8A1C1E0A-6AA4-4F44-9BDF-125A1DE0F1B5 Q39112237-2438EF41-D9AA-4086-A27B-5A4F3E133AFA Q39146320-FA353A21-F4FC-4E55-9FAF-3F255AF65A8C Q39203624-DE83B8CB-0561-4D9F-A2F9-11F5DE9BC0DD Q39254698-2D7E73B5-FD28-4308-948B-9342178914E2 Q39262589-C44BC562-01CF-4BB6-AE29-0809AA1D107F Q39301797-38B22F4B-B4AE-4393-8778-98B7538700FA Q39326974-20D9C6D0-1F72-42A5-B176-9425DA6B2E58 Q39398874-DF03F987-5B75-4788-BFB2-772F1F65574F Q39609174-8FB36917-B2B0-471B-91A3-930A1BC54D30 Q40304087-2CB19211-1596-4C2C-89CE-86575C2E6E5F Q40353248-192AF06C-7F4D-4329-88FF-91AB5B38AD71 Q40399465-94A5C670-1DDF-4756-9371-C323EEE47FF4 Q40438926-D484CFDF-6679-487B-B7F7-5948ACB48E5C Q40629289-CE93C9D5-0C6C-45C4-8BBB-73BBE0653976

P2860

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

http://www.wikidata.org/entity/Q37631758

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Simeprevir plus sofosbuvir in ...... : A phase 3 study (OPTIMIST-2)

@en

Simeprevir plus sofosbuvir in ...... and cirrhosis: A phase 3 study

@nl

type

label

Simeprevir plus sofosbuvir in ...... : A phase 3 study (OPTIMIST-2)

@en

Simeprevir plus sofosbuvir in ...... and cirrhosis: A phase 3 study

@nl

prefLabel

Simeprevir plus sofosbuvir in ...... : A phase 3 study (OPTIMIST-2)

@en

Simeprevir plus sofosbuvir in ...... and cirrhosis: A phase 3 study

@nl

P1433

Q37631758-9FB411C7-E67E-4784-BAD5-7A8256C4A80A

P1476

Q37631758-77B013D8-E8E6-4D7A-9014-564426E6A935

P2093

Q37631758-022D8D39-864C-4383-8C6F-915E7C8FC680

Q37631758-053C740F-8E6C-47A9-837D-00382A6BA370

Q37631758-2577C78B-CEE3-4176-9AE4-B2F466ADB7F5

Q37631758-2E52763B-B66D-417C-951C-4B2C3537FE8A

Q37631758-3E55636C-F661-4D77-98EA-EC45D0243A79

Q37631758-41B02304-1F72-4E1C-BE8F-BB34A5313E3D

Q37631758-42B59B1C-C286-482A-A0A1-CEE6FBDBFF0B

Q37631758-56A7B684-5137-4C59-B44C-8B17DA17F269

Q37631758-7C03AAEA-3074-44A1-8962-F958781FD82D

Q37631758-82597F24-826E-42E7-A735-07011A0C8F23

P2860

Q37631758-0836301E-D1D6-473F-B2E9-9276B672D265

Q37631758-2884A4E1-F564-428F-BAE6-53DBF3D5617B

Q37631758-2FDD11D9-C408-4A55-A6F5-DC2B7C912FB0

Q37631758-30C1A5D2-452E-46A1-84B4-686CF289A026

Q37631758-4D44DBC7-F45D-46A7-B961-A6CD606D5CDC

Q37631758-4E451407-85E0-4023-8154-02C6CEF4E7C2

Q37631758-A16E6566-5979-4EC2-92FE-365C22594E60

Q37631758-AAAC74DC-2E9B-4A36-9AF7-460B22B57E0C

Q37631758-AD223D8F-310C-4E78-829A-7AF52EE3879B

Q37631758-C095CE17-9899-458D-AC76-CED6FACEE688

P304

Q37631758-347BD2AD-E679-4CA1-BF22-6CEA692E0EA8

P31

Q37631758-006A98C1-147C-4593-B3CC-8C1E619D1BB4

P356

Q37631758-BB8376D5-1152-4FCA-A2B8-EDC7C9AF64E4

P407

Q37631758-D2398A6C-3A75-47F0-9BCC-0372F32A74DE

P433

Q37631758-9E867E8B-0CFA-4256-B787-1F14087942A2

P478

Q37631758-C5178EF0-377D-4ED0-BB1A-417F265D8A72

P577

Q37631758-D6852DD8-0021-4BAF-9223-29693F14B3BE

P698

Q37631758-7DA4E84F-890A-491A-80AE-2D4EA6FAE22B

P921

Q37631758-0B7997C4-670A-4068-ADB3-2F62F31A7E73

Q37631758-64BA6E75-6349-45C1-8539-37D4483152DC

Q37631758-7E01A45F-09C1-42A8-88B6-D08D76825FC5

P932

Q37631758-0837A39B-71F3-46FD-B925-8DB530F00EBA

P356

P1433

P1476

Simeprevir plus sofosbuvir in ...... : A phase 3 study (OPTIMIST-2)

@en

P2093

Aasim Sheikh

http://www.w3.org/2001/XMLSchema#string

Bart Fevery

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Eliot Godofsky

http://www.w3.org/2001/XMLSchema#string

Eric Lawitz

http://www.w3.org/2001/XMLSchema#string

Eric M Yoshida

http://www.w3.org/2001/XMLSchema#string

Franco Felizarta

http://www.w3.org/2001/XMLSchema#string

Gary Matusow

http://www.w3.org/2001/XMLSchema#string

Gary Poleynard

http://www.w3.org/2001/XMLSchema#string

Guy De La Rosa

http://www.w3.org/2001/XMLSchema#string

P2860

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

Review of patient-reported outcome measures in chronic hepatitis C

Natural history of hepatitis C

EuroQol--a new facility for the measurement of health-related quality of life

Sofosbuvir for previously untreated chronic hepatitis C infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Treatment of hepatitis C in difficult-to-treat patients.

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

P304

360-369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.28422

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26704148

http://www.w3.org/2001/XMLSchema#string

P921

liver cirrhosis

P932

5297873

http://www.w3.org/2001/XMLSchema#string